Therapeutic decision-making in inhibitor patients.
A panel of hematologists met to discuss treatment choices in patients with hemophilia A and inhibitors. The group agreed that the management of bleeding episodes is complicated by a variable response to bypassing therapy, uncertainties regarding optimal dosing of NovoSeven, and concerns about the combined use of NovoSeven and FEIBA. Thrombotic risk was rated very low for both agents, and there was consensus that product selection should not be restricted to recombinant products. Cost considerations in therapeutic decision-making were also discussed.
Allen
Geoffrey
G
Pediatric Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7220, USA. allen@med.unc.edu
Aledort
Louis
L
D001779:Blood Coagulation Factors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003657:Decision Making; D004338:Drug Combinations; D005167:Factor VII / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology; D015942:Factor VIIa; D006467:Hemophilia A / Q000097:blood / Q000191:economics / Q000276:immunology; D006470:Hemorrhage / Q000191:economics / Q000517:prevention & control*; D006801:Humans; D007518:Isoantibodies / Q000276:immunology; D011994:Recombinant Proteins / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use
D001779:Blood Coagulation Factors; D004338:Drug Combinations; D007518:Isoantibodies; D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; C103587:recombinant FVIIa; C065655:anti-inhibitor coagulant complex; D015942:Factor VIIa